Q-omics provides the consensus-scored LMCD1 profile across patient tissues and cancer cell-line models. LMCD1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LMCD1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, LMCD1 protein abundance shows 36,092 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, COAD, and LUAD as cancer lineages where LMCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LMCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LMCD1 survival associations across molecular data types. LMCD1 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LMCD1 RNA expression–survival associations across cancer types. High LMCD1 expression shows unfavorable associations in LGG, BLCA, ACC and KIRP, but favorable associations in UVM and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LMCD1 RNA expression.
This table summarizes LMCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 12. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LMCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LMCD1 shows lower tumor expression in LUSC, KICH, LUAD and BLCA and higher tumor expression in COAD and LIHC. The COAD box plot shows higher LMCD1 RNA expression in tumor versus normal tissue (log2 FC = +0.969, t-test p < 0.001).
This table shows molecular features associated with LMCD1 in patient tissues and cancer cell lines. In patient samples, LMCD1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LMCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
